by TNG Founding Member Jennifer Dowd
The precise timeline based on clinical trial tracking: Weeks 1-3: Mild symptoms beginning, most patients adapting to medication Weeks 4-8: Peak side effect period highest nausea, GI symptoms at their worst Weeks 9-12: Rapid improvement, most GI symptoms resolving Weeks 13-24: Minimal symptoms for most, discontinuation rate drops to under 2% Weeks 25-48: Essentially no side effects for 85%+, focus shifts to weight maintenance According to research published in the New England Journal of Medicine on GLP-1 agonists, this pattern is consistent across the entire class of incretin-based therapies
If T3 and T4 levels are high, less TSH is secreted, and the reverse occurs when the T3 and T4 levels are too low, when more TSH is secreted
After four weeks at 0.25 mg, doses increase in steps every four weeks, following the pattern below
FFSU accounted for over 98% of the dollars spent and prescriptions filled
Rusch, M